Ethyl (2R,4R)-4-Methyl-2-Piperidinecarboxylate CAS 74892-82-3 Argatroban Intermediate High Purity

Short Description:

Name: Ethyl (2R,4R)-4-Methyl-2-Piperidinecarboxylate 

CAS: 74892-82-3

Appearance: Clear to Light Yellow Liquid

Purity: ≥98.0% (GC)

Intermediate of Argatroban, A Synthetic Antithrombotic Agent

High Quality, Commercial Production

E-mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name Ethyl (2R,4R)-4-Methyl-2-Piperidinecarboxylate
Synonyms Ethyl (2R,4R)-4-Methylpipecolate; (2R,4R)-4-Methyl-2-Piperidinecarboxylate; (2R,4R)-Ethyl 4-Methylpiperidine-2-Carboxylate; Ethyl-(2R,4R)-4-Methylpiperidine-2-Carboxylate
CAS Number 74892-82-3
CAT Number RF-PI267
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C9H17NO2
Molecular Weight 171.24
Shipping Condition Shipped Under Ambient Temperature
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance Clear to Light Yellow Liquid
Diastereoisomer ≤1.0%
Purity / Analysis Method ≥98.0% (GC)
Heavy Metals ≤20ppm
Test Standard Enterprise Standard
Usage Argatroban Intermediate (CAS 74863-84-6) 

Package & Storage:

Package: Bottle, Barrel, 25kg/Barrel, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Advantages:

1

FAQ:

Application:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of Ethyl (2R,4R)-4-Methyl-2-Piperidinecarboxylate (CAS: 74892-82-3) with high quality. Ethyl (2R,4R)-4-Methyl-2-Piperidinecarboxylate (CAS: 74892-82-3) is an intermediate typically in the synthesis of Argatroban Monohydrate (CAS 141396-28-3) or Argatroban (CAS 74863-84-6).

Argatroban Monohydrate is a specific thrombin inhibitor, which is a non-heparin anticoagulant, prevents the formation of thrombi. Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor. In 2000, argatroban was licensed by the Food and Drug Administration (FDA) for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT).

  • Write your message here and send it to us